

NCT ID	NCT06218914
Title	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Phase	Phase 1
Date Added	2024-01-23
Location	California, United States Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05999812
Title	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Phase	Phase 2
Date Added	2023-08-21
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	all trans Retinoic Acid, Atezolizumab, Bevacizumab
Tags	MSS/ MMRp
NCT ID	NCT06008119
Title	Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2023-08-23
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06006923
Title	Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Phase	Phase 2
Date Added	2023-08-23
Location	California, United States Florida, United States Illinois, United States Michigan, United States Pennsylvania, United States Washington, United States

Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSI-H/ MMRd
NCT ID	NCT06010901
Title	A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Phase	Phase 1
Date Added	2023-08-25
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06014502
Title	Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	Arizona, United States California, United States Louisiana, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	IMGS-001
Tags	MSI-H/ MMRd
NCT ID	NCT06013111
Title	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06149481
Title	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase	Phase 1, Phase 2
Date Added	2023-11-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Recruiting
Drugs	N-803, Retifanlimab, SX-682
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06026774
Title	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
Phase	Phase 1
Date Added	2023-09-07
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06055439
Title	A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Phase	Phase 1, Phase 2
Date Added	2023-09-26
Location	Georgia, United States Illinois, United States Pennsylvania, United States Tennessee, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp